Contrary to the narrative of government inefficiency, Medicare's administrative overhead is only 2%. In contrast, private commercial insurers spend 16% of every dollar on administration, advertising, and claim disputes, revealing a major source of bloat in the US healthcare system.

The Centers for Medicare & Medicaid (CMS) avoids cracking down on high-cost oncology drugs because they represent a critical profit center for otherwise low-margin hospitals. Hospitals lobby behind the scenes, arguing that reducing these reimbursements would create systemic issues in the healthcare system, creating a regulatory moat.

A significant hidden cost in the US healthcare system is the administrative expense of price negotiation. For a well-run hospital, the process of billing, negotiating, and receiving reimbursement from insurance companies can consume 2% to 7% of a patient's total bill, adding a substantial layer of inefficiency.

By insuring millions more Americans, the ACA created a new, guaranteed government-backed revenue stream. This made healthcare an extremely attractive and low-risk target for private equity firms, accelerating the industry's financialization.

Official healthcare inflation appears lower than reality because hospitals are currently absorbing rising costs by accepting lower profit margins. This is not sustainable and suggests future price hikes as hospitals pass these costs on to insurers in upcoming negotiation cycles, which occur every two to three years.

While competitors like United and Aetna are prioritizing margins in a tough Medicare Advantage market, Humana is aggressively pursuing growth. This is a high-risk gamble, as new members are typically unprofitable in their first year. The strategy relies on a favorable, and uncertain, future change in government reimbursement rates.

The core driver of high insurance costs is the unregulated and widely variable prices charged for identical products and services. Different insurers pay vastly different amounts for the same thing, a market failure hidden from consumers by fixed co-pays, which ultimately leads to ever-increasing premiums for employers.

Contrary to common assumptions, Medicare patients are often the most financially protected. Private insurance plans with high deductibles can expose patients to more severe out-of-pocket costs, making them a higher-risk group for financial hardship during cancer treatment.

The US government's official inflation statistics for healthcare are often lower than public perception because the underlying price data, negotiated between hospitals and insurers, are considered trade secrets. This forces economists to use lagging or incomplete survey data, creating a disconnect with real-world costs.